Eisenmenger syndrome: current perspectives by Nashat, H et al.
© 2017 Nashat et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. 
php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work 
you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For 
permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
Research Reports in Clinical Cardiology 2017:8 1–12
Research Reports in Clinical Cardiology Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
1
open access to scientific and medical research
R E V I E WOpen Access Full Text Article
http://dx.doi.org/10.2147/RRCC.S117838
Eisenmenger syndrome: current perspectives
Heba Nashat1–3
Aleksander Kempny1–3
Colm McCabe1
Laura C Price1–3
Carl Harries1
Rafael Alonso-Gonzalez1–3
Michael A Gatzoulis1–3
Stephen J Wort1–3
Konstantinos 
Dimopoulos1–3
1Adult Congenital Heart Centre 
and National Centre for Pulmonary 
Hypertension, Royal Brompton 
Hospital, 2National Heart and Lung 
Institute (NHLI), Imperial College, 
3National Institute for Health 
Research (NIHR) Cardiovascular 
Biomedical Research Unit, Royal 
Brompton Hospital and National 
Heart and Lung Institute, Imperial 
College, London, UK
Abstract: Eisenmenger syndrome (ES) is the most severe form of pulmonary arterial hyperten-
sion (PAH) related to congenital heart disease (CHD). It results from a cardiac defect allowing 
significant systemic-to-pulmonary (left-to-right) shunting, which triggers the development of 
pulmonary vascular disease (PVD) if the defect is not repaired in a timely fashion. Once severe 
PVD has developed, the defect cannot be repaired. With advances in pediatric cardiology and 
surgery, the prevalence of ES is steadily falling in developed countries; nonetheless, there will 
always be patients who are unsuitable for repair at the time of diagnosis, or emigrating from 
countries with less advanced healthcare, who will develop ES. ES is a multisystem disorder 
causing chronic hypoxemia and reduced cardiac output resulting in significant morbidity and 
mortality. While lung (plus defect repair) or combined heart and lung transplantation is thought 
be the definitive treatment for ES, transplant organs are a limited resource and long-term results 
are still suboptimal. PAH pharmacotherapy was, until quite recently, largely directed at symptom-
atic relief and had no impact on morbidity and mortality. Targeted PAH therapies have recently 
been proven to be beneficial in various forms of PAH in terms of functional status, progression 
of disease, and prognosis. Data on the effect of PAH therapies in the ES cohort remain limited, 
but available studies demonstrate evidence of improvement in symptoms, exercise capacity, and 
some evidence of survival benefit. ES patients should be followed in specialized centers, by 
means of an interdisciplinary approach by clinicians experienced in PAH and CHD. However, 
local physicians working in cardiology, respiratory medicine, primary care, and emergency 
services are likely to encounter ES patients and need to be aware of the main issues and pitfalls 
in their care. The authors present an overview of the management of ES, focusing on the most 
common issues and complications.
Keywords: Eisenmenger syndrome, pulmonary arterial hypertension, congenital heart disease, 
cyanosis, pulmonary arterial hypertension therapies, hyperviscosity, thrombosis, bleeding, 
pregnancy, Down syndrome
Introduction
Congenital heart disease (CHD) is the most common inborn defect, occurring in ~0.8% 
of neonates.1 With perinatal care and screening programs, including advances in fetal 
echocardiography, affected children are increasingly born into a “prepared” environ-
ment and undergo surgery in a timely fashion, with increasing numbers surviving to 
adulthood.2 It is estimated that up to 10% of adults with CHD develop pulmonary 
arterial hypertension (PAH) of any severity, a disease process that is the result of 
numerous pathological pathways affecting the pulmonary vascular bed, resulting in a 
rise in pulmonary vascular resistance (PVR), right heart failure, and premature death.3
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Eisenmenger syndrome (ES) is the most advanced form 
of PAH associated with CHD (PAH-CHD). In 1897, Dr Victor 
Eisenmenger first reported the case of a man with cyanotic 
heart disease and severe pulmonary hypertension (PH). Dur-
ing the years that followed, the anatomy, pathophysiology, 
and diagnostic features of the abnormalities described in his 
report became better understood and increasingly relevant to 
clinical practice. In 1958, Dr Paul Wood created a structured 
classification of the clinical characteristics of this condition 
based on his observations of 127 patients, and demonstrated 
that ES can develop as a result of large shunts at various 
locations: atrial or ventricular, patent ductus, or aortopulmo-
nary window.4 Long-term exposure of the pulmonary bed to 
increased pulmonary flow and pressure from a post-tricuspid 
(eg, ventricular septal defect [VSD]) left–right shunt results in 
vascular remodeling and dysfunction. This, in turn, leads to a 
rise in PVR, which, if severe enough, results in reversal of the 
shunt and the clinical cyanosis characteristic of ES. Once ES 
is established, the defect is no longer surgically correctable, 
as it is felt to act as a relief valve for the right ventricle (RV).5
The exact prevalence of ES is not known. According to 
historical data and before the advent of timely intervention, 
~8% of patients with CHD and 11% of those with left-to-right 
shunts developed ES.6,7 Enhanced understanding and timely 
surgical or interventional repair of defects has resulted in 
a substantial reduction in the numbers of patients develop-
ing ES. Nevertheless, this condition will continue to occur 
in patients unsuitable for early repair and individuals from 
countries where availability of tertiary pediatric cardiology 
and cardiothoracic surgery is limited.
Anatomical variations in patients 
with ES and outcome
The classification of PH was first developed in 1998 and the 
condition was categorized into groups that shared similar 
pathological, hemodynamic characteristics, and therapeutic 
approaches. The current classification in use was finalized at 
the fifth World Health Organization (WHO) meeting in 2013 
by Simonneau et al.8 The classification comprises of five 
groups. Group 1 is PAH, to which PAH-CHD belongs as a 
type of “associated PAH”. PAH-CHD is further divided into 
four main anatomic subgroups, of which ES is one (Table 1).8 
The frequency of PH in these types of CHD and the subse-
quent development of right-to-left shunting vary depending 
on the size and location of the defect and whether previous 
intervention has been performed.9 ES is typically associated 
with large, nonrestrictive intra- or extra-cardiac communica-
tions. These include VSDs, atrial septal defects (ASDs), an 
aortopulmonary window, or a patent ductus arteriosus.
Observational studies have shown that there may be dif-
ferences in the natural course and ventricular adaptation to 
long-standing pulmonary vascular disease, depending on the 
location of the defect in ES patients and the presence of a 
uni- or biventricular heart. In an echocardiographic study of 
191 patients with ES and noncomplex CHD, the location of 
the defect was associated with different physiological adapta-
tion of the RV to the PAH and, possibly, a different prognosis: 
pre-tricuspid shunts were older, had larger RVs, and a trend 
toward worse prognosis when compared to post-tricuspid 
lesions.10,11 Indeed, the mechanisms behind shunt reversal in 
ES ASD patients differs significantly to post-tricuspid shunts, 
depending significantly on the relative compliance of the left 
and right ventricles and, perhaps, less so on the ratio between 
systemic and pulmonary resistances.
General management of 
Eisenmenger syndrome
Although patients with ES can survive into the fourth and 
fifth decades of life, their condition is associated with high 
morbidity, reduced functional status, and frequent hospital-
izations. In ES, the chronic hypoxemia, together with a low 
cardiac output and PAH, has significant multisystem effects, 
resulting in a vast spectrum of complications (Table 2).5,12–15 
Cardiac arrhythmias, hemoptysis, infections, and right heart 
failure are important late complications and are a frequent 
cause of death. Other complications such as pulmonary 
artery (PA) dilatation and in situ thrombosis are frequently 
encountered in this cohort (Figure 1).
Table 1 Clinical classification of pulmonary arterial hypertension 
associated with congenital heart disease
Eisenmenger 
syndrome
All large intra- and extra-cardiac systemic-to-pulmonary 
shunts with reversal or bidirectional shunting, 
cyanosis, secondary erythrocytosis, and multiple organ 
involvement
Associated with severe elevation in PVR
ASD >2 cm, VSD >1 cm
Left-to-right 
shunts
Correctable and non-correctable
Moderate to large defects
PVR is mild to moderately increased
No cyanosis
PAH with 
coincidental 
congenital 
small defects
Marked elevation in PVR in the presence of small 
defect which do not account for the development of 
elevated PVR.
ASDs <2 cm, VSDs <1 cm
Clinically similar to idiopathic PAH
Defect closure is contraindicated
Postoperative 
PAH
Post repair PAH persists after surgery or develops 
months/years after surgery in the absence of 
postoperative hemodynamic lesions
Abbreviations: ASD, atrial septal defect; PAH, pulmonary arterial hypertension; 
PVR, pulmonary vascular resistance; VSD, ventricular septal defect.
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The anticipation and timely management of potentially 
specific complications arising from cyanosis due to the 
right-to-left shunt and associated morbidities, such as iron 
deficiency, thrombosis, gout, renal dysfunction, cholelithia-
sis, and cerebral infections (Figure 2), are just as important to 
consider as the specific treatment of the PAH with therapies.
Current guidelines in the management of patients with ES 
recommend regular consultations with experienced physicians 
in CHD and PH.15 Areas that require routine consideration are 
detailed in the following sections, but also include adequate 
contraception, endocarditis prophylaxis, up-to-date immu-
nization against influenza, and pneumococcal infections.16
Before the advent of PAH-specific therapies, medical 
treatment was restricted to diuretics, anticoagulation, digoxin, 
β-blockers, and antiarrhythmics, mainly for symptomatic 
relief with limited evidence. β-blockers and calcium chan-
nel blockers are generally contraindicated in PAH due to the 
negative inotropic effect on the RV.17 Unlike left-sided heart 
failure, β-blockers have not yet been shown to improve RV 
function but may be used in specialist PH centers for other 
indications such as prevention of recurrent arrhythmias in 
small doses. More recently, animal studies have shown a 
potential role for β-blocker therapy to protect RV function 
and their use in idiopathic PAH (iPAH) is currently being 
assessed in clinical trials.18,19 Moreover, patients with ES often 
have diastolic impairment, if there is a need for heart rate 
Figure 1 Computed tomography of a patient with a patent ductus arteriosus demonstrating dilated PA compared to the aorta (A), typically seen in Eisenmenger syndrome. 
In situ thrombosis (B, arrows) is also a common complication in patients with Eisenmenger syndrome.
Abbreviation: PA, pulmonary artery.
a
a
b
Aorta
PA
Aorta
PA
A B
Table 2 Complications of Eisenmenger syndrome
Cardiac Arrhythmias
Conduction disease
Heart failure
Valve diseasea
Pulmonary artery dilationb
Coronary artery compression
Syncope
Sudden cardiac death
Noncardiac Bleedingc
In situ thrombus in the pulmonary artery
Embolic phenomenad
Renal dysfunction
Hyperviscositye
Iron deficiency
Infectionsf
Gout
Cholelithiasis
Hyponatremia
Hypertrophic osteoarthropathy
Notes: aTricuspid or pulmonary valve regurgitation. bMay cause extrinsic compression 
of coronary arteries or PA dissection. cMay be pulmonary, gastrointestinal, or 
cerebral. dMay be pulmonary or cerebral/systemic. eSymptoms may include headache, 
dizziness, visual disturbance, altered mental state, tinnitus, and fatigue. fImportant to 
consider endocarditis or cerebral abscess.
Abbreviation: PA, pulmonary artery.
Figure 2 Cerebral abscess with surrounding edema and midline shift in a patient 
with VSD and ES presenting with syncope and a mild fever.
Abbreviation: ES, Eisenmenger syndrome; VSD, ventricular septal defects.
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control, then β-blockers are at times favored over digoxin as 
they improve diastolic filling time and potentially optimize 
symptoms, albeit with no robust evidence. Interestingly, in a 
study of 153 patients with ES, Diller et al noted a trend toward 
better survival in patients on β-blockers in their analysis.20
While the natriuretic peptide, sympatho-adrenergic, and 
renin–angiotensin–aldosterone systems are activated as a 
result of abnormal distension of cardiac chambers, these are 
not currently targets for therapy in ES, with the exception 
of aldosterone antagonists.21 Aldosterone antagonists (eg, 
spironolactone) and loop diuretics are often used in these 
patients. However, the use of diuretics should be carefully 
monitored as dehydration and significant fluid shifts may 
exacerbate a right-to-left shunt, thus worsening the cyano-
sis, potentiating renal dysfunction, and increasing the risk 
of thromboembolism. Hyperaldosteronism is common in 
RV dysfunction in PH and is often used in conjunction with 
other diuretics, albeit with very limited evidence. Tradition-
ally, angiotensin-converting enzyme (ACE) inhibitors and 
angiotensin II receptor blockers (ARBs) have been avoided in 
patients with ES because of the potential worsening of cyano-
sis from an increase in a right-to-left shunt as a consequence 
of the reduction of the systemic vascular resistance (SVR).22 
However, evidence in this is limited and ambiguous. A study 
of 60 patients with cyanotic heart disease examined the effect 
of ACE inhibition and did not report a significant reduction in 
oxygen saturation, but a potential improvement in functional 
class and quality of life.23 Moreover, in a German registry 
of 153 patients with ES of various cardiac anatomies, ~10% 
were on ACE-i/ARBs with no significant association between 
ACE-i/ARBs and their outcome.24
Hyperuricemia and gout are also common in ES and 
administration of uricosuric or uricostatic agents is indicated 
in patients with recurrent gouty arthritis. In the acute phase, 
symptoms can be relieved by oral colchicine or intraarticular 
corticosteroids, as indicated. Asymptomatic hyperuricemia 
is not an indication for routine drug therapy.25
Secondary erythrocytosis, iron 
deficiency, and venesection
The effect of chronic hypoxemia causes a compensatory 
secondary erythrocytosis aimed at increasing the blood’s 
oxygen-binding capacity. This process requires substantial 
iron stores for the production of hemoglobin (Hb) and is 
likely the main cause of the iron deficiency commonly 
found in cyanotic patients.26 Prophylactic or routine vene-
section to maintain a hematocrit level within an arbitrary 
predetermined level (hematocrit <65%) is not indicated.27,28 
This is one of the major misconceptions in the management 
of patients with cyanotic CHD and routine venesection 
can be harmful to these patients, as they can result in iron 
deficiency, reduced exercise tolerance, impaired oxygen 
transport capacity due to “relative anemia”, and may 
increase the risk of cerebrovascular events.29,30 Venesection 
should only be offered to patients with moderate-to-severe 
hyperviscosity symptoms (Table 3) due to significant sec-
ondary erythrocytosis (Hb level well above 24 g/dL) in the 
absence of volume depletion/dehydration.31 Also, venesec-
tion can be considered preoperatively for autologous blood 
donation if the hematocrit level is >65% and for boosting 
platelet production.32
Iron deficiency is a common complication in patients with 
ES.33 “Relative anemia” is often not recognized in cyanotic 
patients: a Hb concentration, which drops to levels that are 
normal for the general population, is often suboptimal for 
cyanotic individuals.27
Beyond high iron requirements and inappropriate vene-
sections, other contributors to iron deficiency and relative 
anemia include bleeding and the use of oral anticoagulants 
(OACs). Hemoptysis, epistaxis, menorrhagia, and gastro-
intestinal bleeding are not uncommon in ES and may be 
difficult to manage. Iron supplementation is recommended, 
especially when Hb concentration is significantly below 
the level expected for the patient’s oxygen saturation, but 
excessive erythrocytosis causing hyperviscosity symptoms 
(Table 3) should be monitored. A study of 68 patients by Van 
De Bruaene et al found that patients with resting oxygen 
saturations of <83% often reached Hb concentrations in the 
range that may be considered “at risk” for hyperviscosity 
symptoms when treated for iron deficiency and suggested 
closer monitoring for hyperviscosity symptoms in this 
group.34 As iron deficiency is strongly related to adverse 
outcomes, particularly in those on anticoagulation or those 
having inappropriate venesection, it is important to regularly 
screen patients for this and treat when appropriate.
Oxygen therapy
The use of oxygen supplementation in patients with ES is 
controversial. It has been shown to have no impact on exercise 
capacity and survival in adult patients with this condition.35 
However, some may benefit from nocturnal supplementation 
for symptomatic relief, and oxygen may be useful in patients 
with advanced disease and in those awaiting heart–lung 
transplants. Air travel appears to be safe, as long as airplanes 
are adequately pressurized.29,36 Supplemental oxygen during 
commercial air travel is not routinely required, especially for 
shorter flights up to 4 hours. It can, however, be administered 
for symptomatic benefit on for longer flights.32
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Anticoagulation
Patients with ES are at an increased risk of PA thrombosis. 
A retrospective analysis by Silversides et al found that, of 34 
patients with ES, 21% had evidence of proximal PA throm-
bus. These patients were more likely to be women and have 
lower oxygen saturations and advanced disease with worse 
ventricular dysfunction, exercise intolerance, and natriuretic 
peptide levels.37 On the other hand, ES patients are also at an 
increased risk of bleeding, including potentially life-threatening 
pulmonary hemorrhage. It is not routine to anticoagulate 
patients with ES, unless there are coexisting conditions such 
as atrial fibrillation, pulmonary thromboembolic, congestive 
heart failure, or embolic events in the absence of significant 
hemoptysis or other bleeding risks. OACs are associated with 
an increased risk of iron deficiency anemia and patients should 
be routinely investigated for this.34 Also, endothelin receptor 
antagonists (ERAs) can reduce the efficacy of anticoagulants 
such as warfarin; therefore, necessitate close monitoring of 
the international normalized ratio is needed to maintain an 
adequate therapeutic index. Novel OACs have not been tested 
in this group and there are concerns regarding the limited avail-
ability of direct reversing agents. With the recent Food and Drug 
Administration (FDA) approval of iarucizumab for reversal of 
dabigatran, this may become an option in the future.38
Exercise training
Exercise training (ET) should not be discouraged in patients 
with ES.39 In patients with severe heart failure, regular train-
ing improves endothelial function in systemic vessels and 
long-term outcome.40,41 Impaired skeletal muscle function has 
been described in CHD and is a potential target for rehabilita-
tion/ET.42 Mild-to-moderate aerobic activity and low-level 
resistance exercises can be safely performed in most clinically 
stable patients. The recommendation for patients with ES is low 
dynamic sport leisure activities with a low isometric (static) 
component, while competitive sports are contraindicated. 
Highly isometric exercise (eg, weight lifting) should be avoided. 
Patients with a persistent shunt should avoid scuba diving.43
Noncardiac surgery
PAH, CHD, and ES are known risk factors for periopera-
tive complications.44 Patients with PAH are often counseled 
against elective surgery because of the risk of early and sudden 
postoperative deaths. In PAH, the RV cannot accommodate 
large alterations in preload or afterload induced by fluid shift, 
anesthetic medication, insufflation of gas in the abdomen during 
laparoscopic procedures, or autonomic changes precipitated by 
hypoxia or hypercapnia, which are magnified by stress or pain. 
RV ischemia, resulting in worsening RV function, can be precipi-
tated by systemic hypotension and arrhythmias during surgery.45 
Therefore, the choice of anesthetic is crucial for patients with 
PAH. The same principles of risk management apply to ES.
The two main principles of perioperative risk management 
are the prevention of systemic hypotension and avoidance of 
an increase in PVR (PH crisis). Specific risks during surgery 
include arrhythmias, thromboembolism, and bleeding and 
sudden changes in SVR. Close monitoring, optimization of 
systemic blood pressure, pain control, oxygenation and ventila-
tion, avoidance of exacerbating factors, and use of vasopressors 
and pulmonary therapies, as necessary, are essential elements 
of perioperative management. In a study of 33 ES patients 
undergoing general or regional anesthesia, 26% experienced 
profound hypotension and 17% a drop in oxygen saturation. 
Bennett et al found that vasopressor agents given during 
induction significantly reduced the incidence of hypotension.46
Patients with an underlying cardiac condition, which 
includes any cyanotic CHD, are at higher risk of infective 
endocarditis and should receive prophylaxis. This, however, 
only applies to high-risk procedures, which are mainly invasive 
dental procedures, and not for respiratory tract procedures, 
gastrointestinal/urogenital, or skin/soft tissue procedures.16
Transplantation
The only definitive treatment for ES is lung transplantation 
(LT) with shunt closure or heart and lung transplantation 
(HLT). In a a worldwide registry of 605 transplanted ES 
patients over a 10-year period, Waddell et al found that, 
in this heterogeneous group, post-transplantation survival 
related to the underlying cause of the ES, and HLT appeared 
to be better than LT with shunt correction: 30 days and 
1-year survival rates were 80.7% and 70.1% compared 
with 68% and 55.2%, respectively.47 In another study of 
51 patients with ES transplanted in the UK, the 1-, 5-, and 
Table 3 Hyperviscosity symptoms
Bleeding Mucosal
Epistaxis
Rectal
Menorrhagia
Persistent bleeding from cuts/minor procedures 
Visual  
changes
Blurred vision
Complete visual loss
Neurological Vertigo
Hearing loss
Paraesthesia
Ataxia
Headaches
Seizures
Somnolence progressing to stupor and coma 
Note: Hyperviscosity symptoms consist principally of the triad of mucosal bleeding, 
visual changes, and neurologic symptoms.
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10-year survival rates for ES were 72.6%, 51.3%, and 27.6%, 
respectively, compared to non-ES of 74%, 48.1%, and 26%, 
respectively with no difference in survival overall.48 Even 
though it has been suggested that patients with ES may 
have a better post-transplantation prognosis than patients 
with iPAH or other types of congenital heart defects, the 
general lack of organs and suboptimal survival after LT or 
HLT underline the need for alternative therapeutic options.49
Disease-specific targeted PAH therapy
The mainstay of PAH treatment is, nowadays, specific 
disease-targeting pulmonary therapies, which have only 
been in use since the 1990s. Acute vasoreactivity testing 
with nitric oxide (NO) and subsequent therapy with calcium 
channel blockers in responders is established in iPAH, but 
no evidence is available in PAH-CHD. The use of calcium 
channel blockers is, in fact, discouraged in ES, as they may 
cause significant peripheral vasodilatation and hypoxia.50
So far, only three pathomechanistic pathways in PAH 
have been translated into clinical practice: prostacyclin, nitric 
oxide, and endothelin pathways. Oral and parenteral therapies 
have been designed to target these pathways, namely pros-
tanoids, phosphodiesterase type-5 inhibitors (PDE-5i), and 
ERAs. Other substances, such as soluble guanylate cyclase 
inhibitors, which target the same pathways as PDE-5i are 
becoming available; however, their role in ES has not been 
established. There are very few randomized data on specific 
pulmonary therapies in ES, with further support from a num-
ber of prospective, open-label, and retrospective studies.51–54
Despite the associated functional limitations and multitude 
of comorbidities, survival prospects in adults with ES are gener-
ally considered better than in other forms of PAH, but mortality 
remains high. In a systematic review of literature and reanalysis 
of data in treatment-naïve patients with ES, Diller et al found 
that after adjusting for immortal time bias, the 10-year mortality 
in 1,131 patients from 12 studies was 30%–40% and survival 
prospects have not considerably improved over the last decade 
in untreated patients.20 However, registry data have shown bet-
ter survival prospects in ES patients on pulmonary therapies 
disease when compared to those who were treatment naïve.24,55
Endothelin-1 receptor antagonists
ET-1 (Endothelin-1) is a powerful vasoconstrictor, pro-
duced in endothelial cells, with elevated concentrations 
seen in patients with PAH. ET-1 plays a key role in the 
pathogenesis of PAH by inducing proliferation, fibrosis, 
and  inflammation.56 These effects are mediated through the 
endothelin receptor subtypes A (ET
A
) and B (ET
B
) on which 
orally active ERAs selectively target either a single receptor 
(ET
A
) or both receptors (ET
A 
and ET
B
). Commercially avail-
able ERAs are ambrisentan, which targets a single receptor 
ET
A
, and bosentan and macitentan that target both receptors. 
A fourth ERA targeting a single receptor, sitaxentan, was 
withdrawn in 2010 due to two cases of fatal hepatic failure.
Bosentan was the first drug in this category to be approved 
by the FDA and the European Medicines Agency in 2002 for 
the treatment of PAH. Its specific use in patients with ES is 
supported by the first ever randomized control trial (RCT) of 
PAH therapies in this cohort. Bosentan Randomized Trial of 
Endothelin Antagonist Therapy-5 was a multicenter, double-
blind, randomized, placebo-controlled study of 54 patients 
with ES, assessing the safety and efficacy of bosentan as an 
endpoint in this cohort. Sixteen weeks of therapy resulted in 
significant improvement in hemodynamics and 6-minute walk 
distance (6MWD), without adversely affecting systemic arte-
rial oxygenation.52 These positive findings were maintained in 
the open-label extension up to 40 weeks.57 Bosentan is cur-
rently endorsed as the first-line choice of treatment in patients 
with ES in the WHO functional class III–IV. A caution with 
this drug is that in 10% of cases there is an increase in hepatic 
aminotransferases, which is reversible by dose reduction or 
discontinuation. For this reason, monthly liver function tests 
should be performed in patients receiving bosentan. Further-
more, interaction with progesterone-based contraception 
means that double contraception is recommended.
Ambrisentan is a selective mono-antagonist of the ET
A
 
receptor with a longer half-life allowing for once-a-day dos-
ing. Unlike bosentan, there are no RCTs or prospective stud-
ies of ambrisentan in ES. A retrospective study by  Zuckerman 
et al in patients with CHD showed improvement in 6MWD 
without any adverse outcome in arterial saturations or serious 
adverse events.58 Liver function abnormalities are less com-
mon with this ERA, ranging from 0.8% to 3%: monthly blood 
tests are required in the UK, but not in the United States.
Macitentan, similar to bosentan, is a dual ET receptor 
antagonist and has been evaluated in a large event-driven RCT 
on patients with PAH (not ES). The Study with Endothelin 
Receptor Antagonist in Pulmoanry Arterial Hypertension 
to Improve Clinical Outcome (SERAPHIN) included 565 
patients with PAH and ~8% of these had PAH after repair of a 
congenital shunt. When compared to placebo, macitentan sig-
nificantly reduced morbidity/mortality and increased exercise 
capacity. There were no cases of liver toxicity, but a reduction 
in Hb was commonly seen.59 Concurrently, the clinical study 
to evaluate the effects of macitentan on exercise capacity in 
subjects with Eisenmenger syndrome; MAESTRO, an RCT 
is underway with an aim to evaluate the effect of macitentan 
on 6 minute walk distances in patients with ES.60
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Phosphodiesterasetype-5 inhibitors and guanylate 
cyclase stimulators
Phosphodiesterases are a group of enzymes that inactivate 
cyclic adenosine monophosphate (cAMP) and guanosine 
monophosphate (cGMP), which are expressed abundantly in 
lung tissue and are upregulated in patients with PAH.61 Inhi-
bition of these enzymes results in vasodilation through NO/
cGMP pathways in sites in which they are most dense. PDE-5i 
clinically acts as potent vasodilators and also has an anti-
proliferative effect. Tadalafil and sildenafil selectively inhibit 
the phosphodiesterase type-5 enzymes. Oral administration 
is not associated with hepatic toxicity; therefore, patients do 
not require regular blood testing. As the CYP3A4 pathway 
metabolizes these drugs, caution should be exercised when 
prescribing them with CYP3A4 inhibitors and inducers.62
Two small RCTs have been published in ES evaluating the 
effect of PDE-5i in a total of 48 patients. These studies dem-
onstrated improvements in 6MWD, functional class, PA pres-
sures invasively, and by echocardiographic parameters.53,63 
Further prospective studies have supported the enhancing 
effects of PDE-5i in patients with ES.64,65 However, because 
the evidence level is lower than that of ERAs, PDE-5i are 
often used as second-line disease targeting therapy.
Riociguat is a relatively new drug in PAH. Unlike PDE-
5i that acts on the NO/cGMP pathway to slow down cGMP 
degradation, guanylate cycle stimulators (sGCs) enhance the 
production of cGMP, a potent vasodilator. It has been tested 
by means of an RCT and has shown favorable results in 
exercise capacity, hemodynamics, functional class, and time 
to clinical worsening in patients with PAH.66 It was most ben-
eficial when combined with other disease-targeted therapy, 
but combination with a PDE-5i is contraindicated due the 
risk of profound hypotension.67 Rosenkranz et al explored the 
efficacy and safety of riociguat in the subgroup of 35 patients 
with repaired CHD included in the PATENT-1 trial and its 
open-label extension, PATENT-2. They concluded that sGCs 
are well tolerated and improved outcomes, including 6MWD, 
PVR, functional class, and N-terminal pro–B-type natriuretic 
peptide.68 Thus, riociguat is a valid alternative to PDE-5i in 
the future, but data on ES are lacking. Moreover, as yet, there 
are no head-to-head comparisons between sGCs and PDE-
5i; therefore, its use in patients with CHD remains limited.
Prostacyclin analogs and prostacyclin receptor 
agonists
Prostacyclin is produced predominantly in endothelial cells 
and induces potent vasodilatation of all vascular beds by 
stimulating the production of cAMP and inhibiting growth of 
smooth muscle cells. It is an endogenous inhibitor of platelet 
aggregation and is cytoprotective and antiproliferative.69 A 
dysregulation of the prostacyclin pathway has been impli-
cated in PAH, thus, it is a target for pharmacotherapy. Clinical 
use of prostacyclin has expanded thanks to the production of 
stable analogs that have different pharmacokinetic proper-
ties but share similar pharmacodynamic effects. Infusion of 
prostacyclin was the first therapy shown to reduce mortality 
in a controlled study of patients with severe iPAH. However, 
prostacyclin can only be administered through an intravenous, 
subcutaneous, or nebulized (inhaled) route, which can influ-
ence patients’ compliance, tolerance, and increase the risk 
of infection when tunneled catheters are used. Intravenous 
infusions, particularly in the setting of a right-to-left shunt, 
may increase the risk of thrombotic and infective complica-
tions related to the line, including endocarditis or cerebral 
abscesses. Therefore, subcutaneous or nebulized administra-
tion is more appealing for this cohort. Moreover, in patients 
with right-to-left shunting systemic side effects are common, 
reducing tolerance and the ability to uptitrate the dose, while 
an abrupt interruption may result in rebound PH, deteriora-
tion, and even death.
Beraprost is an orally active prostacyclin analog, currently 
in use in Japan. In an RCT in 130 patients, improvements in 
exercise capacity at 6 months were observed, but there was 
no hemodynamic improvement or long-term outcome ben-
efits.70 Its use in ES is limited and is associated with frequent 
adverse events such as headache, flushing, jaw pain, and 
diarrhea. Since 2013, oral treprostinil has been available in 
the USA. In the initial primary efficacy study, oral treprostinil 
in combination with an ERA and/or a PDE-5i for the treat-
ment of PAH trial (FREEDOM-M), patients demonstrated 
an improvement in their 6MWD when compared to those 
receiving placebo. In further phase-3 studies, FREEDOM-
C and FREEDOM-C2, no significant benefit was seen in 
exercise with median 6MWD. Furthermore, all patients with 
PAH-CHD had repaired defects.71,72
Epoprostenol, a synthetic prostacyclin, has a short half-
life (3–5 minutes) and requires continuous administration by 
means of an infusion pump and permanent tunneled catheter. 
Epoprostenol has been well studied in patients with iPAH 
and has shown improvements in exercise capacity, quality of 
life, and hemodynamics.73 Similar improvements have been 
reported in small cohorts of patients with ES.74 A case series 
of eight ES patients on intravenous epoprostenol showed 
improved oxygenation and 6MWDs after treatment.75 How-
ever, data are limited and epoprostenol is currently mainly 
used as a third-line agent in patients with ES. Fears of a high 
risk of endocarditis or systemic embolic events with intrave-
nous epoprostenol in ES are not supported by available data.
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Iloprost is a chemically stable prostacyclin analog avail-
able as intravenous, oral, or aerosol administration. The 
inhaled form is felt to be more pulmonary selective and, 
therefore, minimizes systemic side effects.76 In this form, it 
requires 6–8 inhalations a day due to its 25 minutes half-life. 
In PAH and chronic thromboembolic PH, an RCT evaluat-
ing repeated iloprost inhalations when compared to placebo 
showed an increase in exercise capacity and improvement in 
symptoms, PVR, and clinical events.77 Intravenous iloprost 
is thought to be as effective as epoprostenol. The effects of 
oral iloprost have not been assessed in PAH.
Treprostinil is another stable prostacyclin, with a longer 
half-life of 3 hours. It is currently available for subcutaneous 
and intravenous administration. Data on its use in the con-
genital population is extrapolated from a large RCT of various 
forms of PAH, of which 24% had PAH-CHD. There were 
benefits in exercise capacity, hemodynamics, and clinical 
events, but a high frequency of site pain limits subcutaneous 
administration.78 Evidence on the intravenous administration 
of treprostinil in PAH-CHD is very limited.79 Nonetheless, 
long-term use of treprostinil is felt to have similar survival 
benefits as intravenous epoprostenol.80
Selexipag is one of the latest pulmonary therapies to be 
tested in PAH. It is an orally available selective prostacyclin 
IP receptor agonist. Although, its mode of action is similar 
to that of endogenous prostacyclin, by means of IP receptor 
agonism, it is pharmacologically distinct from prostacyclin. 
An initial phase-2 proof of concept pilot RCT examining 
the safety and efficacy of selexipag in PAH patients showed 
a reduction in PVR after 17 weeks of treatment. Safety was 
evaluated in relation to the frequency of treatment-emergent 
adverse events, premature study drug discontinuation, changes 
from baseline measurements of vital signs, ECG, and labora-
tory parameters.81 An event-driven phase-3 RCT of selexipag 
versus placebo followed 923 patients, 10% of which had PAH 
associated with a corrected congenital shunt. This trial showed 
that selexipag alone or in combination with an ERA and/or a 
PDE-5i reduced composite morbidity and mortality by 40% 
(hazard ratio 0.6, P<0.001).82 Currently, there are no data on 
the use of selexipag in patients with ES; however, this drug 
is a likely contender for investigation in this group.
Combination therapy
There is limited information on the efficacy of combination 
therapy in ES, even though most experts feel that combining 
therapies and targeting different pathomechanistic pathways 
improve results. Increasingly, the evidenced-based trend in 
iPAH is to treat patients aggressively with upfront or early 
sequential double or triple therapy, as early initiation of 
combination therapy is believed to delay disease progres-
sion and improve survival.83,84 This is reflected in the 2015 
European Respiratory Society/European Society of Cardiol-
ogy consensus guidelines on the management PH, whereby 
the treatment algorithm now suggests upfront combination 
therapy, even in those with less severe disease.62 As yet there 
are no studies to test upfront combination therapy against 
aggressive sequential therapy, thus, the application of either 
option remains at the discretion of the clinician.
Conversely, adult patients with ES often have prevalent 
established disease and are stable for long periods. Sequen-
tially adding second- and third-line agents appear acceptable 
for those failing to meet clinical targets or with evidence of 
deterioration. One randomized double-blind crossover trial 
evaluated the effect of combination therapy with sildenafil 
and bosentan in 21 patients with ES. They found that bosentan 
alone significantly improved 6MWD, PVR, and pulmonary 
blood flow. When combined with sildenafil, there was no 
further improvement in walk distance; however, there was 
an increase in oxygen saturations at rest.54 In a prospective 
open-label study, D’Alto et al also studied the combined 
effect of bosentan and sildenafil in ES patients and reported 
an improvement in functional class.85 Interestingly, Diller 
et al showed no survival benefit on direct comparison of 
patients with combination therapy versus monotherapy.24 
However, patients on combination therapy likely represented 
a sicker population with more advanced symptoms, hence 
making direct comparison unreliable. These results should 
not preclude escalation of therapy in ES, whereby alleviation 
of symptoms and exercise capacity maybe associated with 
clinical stabilization and may indeed have an impact on sur-
vival over time.24 ES is a progressive condition, which often 
requires sequential treatment escalation, whereas upfront 
combination therapy is currently not routinely used.
ES in patients with Down syndrome
Down syndrome (DS) is a well-recognized genetic condition 
associated with several medical morbidities, intellectual dis-
ability, and characteristic physical features. In patients with 
DS, there is a high prevalence of congenital heart defects in 
the order of 40%–60% and is a major cause of both morbidity 
and mortality in this group. An atrioventricular septal defect 
is the most common structural abnormality, while other 
abnormalities such as mitral valve prolapse may develop 
later in life.86 Children with DS and CHD develop progres-
sive pulmonary vascular changes earlier than those without 
DS with similar CHD, possibly due to intrinsic endothelial 
dysfunction of the pulmonary vasculature and elevation of 
plasma levels of asymmetric dimethyl arginine, which might 
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contribute to the development of PH.87,88 Despite the signifi-
cant disease burden in this population, data are very limited 
on the use of PAH therapies and there are no randomized 
clinical trials in this population. In an attempt to reflect the 
success of bosentan in patients with ES, an open-label study 
of 28 patients with DS were followed up for 11.5 months 
confirming that this drug was well tolerated with no serious 
adverse events and significant improvement in walk distance 
but no changes in quality of life questionnaires.89 However, 
concerns on the validity of 6MWD tests, reliability of qual-
ity of life questionnaires, patient compliance to treatment or 
regular blood monitoring, and the risks related to invasive 
assessments such as the need for general anesthesia make the 
evaluation and management challenging in patients with DS. 
In the United States, hospitalizations for patients with DS/
CHD are decreasing but those who are hospitalized are more 
likely to die during admission but less likely to undergo a 
cardiac procedure.90 A multidisciplinary approach in special-
ist centers is advocated to enable the management of ES in 
patients with DS.91
Pregnancy in patients with ES
Maternal mortality in the presence of ES is extremely high 
and has not improved sufficiently in the last 2 decades, despite 
advances in treatment.92–94 Mortality rates remain worryingly 
high, at 30%–50% for the expectant mother and, as a result, 
patients are strongly advised to avoid pregnancy. Many 
women with ES are also often treated with pulmonary thera-
pies, which are teratogenic (ERAs), while cyanosis makes 
spontaneous abortions likely. Also, the expectant mother with 
ES should be advised on the risk of transmission of CHD 
to her offspring, varying from 3% to 5% compared with 1% 
risk for the general population.95
Unfortunately, some women who are fully informed and 
understand the maternal and fetal risk and complications may 
still become pregnant, while others who are lost to special-
ist follow-up may present pregnant without having received 
appropriate preconception counseling. If a patient decides 
to continue her pregnancy, careful follow-up in centers with 
appropriate experience in ES, CHD, high-risk obstetrics, 
anesthesia, and intensive care, so as to manage complications 
promptly and appropriately. Patients on warfarin are at risk 
of fetal embryopathy. In a study by Vitale et al, they found 
no cases of embryopathy in women taking a dose of <5 mg/
day.96 However, these figures have not been replicated in other 
studies, with other groups reporting a 5% risk of embryopa-
thy in women taking <5 mg/day and 7% for those taking >5 
mg/day.97 It is recommended that women who must remain 
on some form of anticoagulation throughout pregnancy are 
prescribed either unfractionated heparin or low-molecular-
weight heparin in their first and third trimesters and warfarin 
in the second trimester, as optimum anticoagulation particu-
larly for mechanical valves is best achieved with warfarin. 
ERAs are teratogenic and should be discontinued. ERAs can 
be replaced by PDE-5i and prostanoids that pose less of a 
fetal risk. Inhaled NO or intravenous prostanoids may also 
be used in the intensive care unit if a pulmonary hypertensive 
crisis or right ventricular failure occurs, which can occur up 
to several weeks postpartum.61
A discussion about contraceptive methods is imperative, 
especially if patients are on bosentan. Progesterone-only for-
mulations, such as depot injections and subdermal implants, 
are a reasonable option; however, progesterone-only pills 
alone are not optimal because of unacceptably low efficacy 
rates. Contraceptive pills containing estrogen are contraindi-
cated due to an increased risk of thromboembolism.95 Double 
contraception (with barrier methods) is recommended, espe-
cially in patients on bosentan, due to the high teratogenicity 
and an interaction, which reduces the contraceptive efficacy.
Intrauterine devices are effective, but may convey a certain 
risk of infection, with the greatest fear being endocarditis. 
Possible vasovagal events during insertion can be poorly tol-
erated by the patient, hence should be performed in hospital. 
Sterilization is an option, but a laparoscopic procedure carries 
a high intraoperative risk: beyond the risks relating to the 
anesthetic and reduced cardiac output from positive pressure 
ventilation, insufflation of the abdomen with carbon dioxide, 
arrhythmias, bleeding, and air embolism are also of concern.
Conclusion
In the modern era of more sophisticated medical and surgical 
management of CHD, the number of patients who develop 
ES is dropping rapidly; thanks to timely repair of the defect. 
However, a small proportion of CHD patients in developed 
countries and many more in developing countries still develop 
ES, a severe and debilitating condition, which affects the indi-
vidual’s capacity for exertion, reproduction, and quality of life. 
ES patients have benefitted greatly from recent advances in 
the management of this condition, especially the introduction 
of PAH therapies. Further work needs to be done to improve 
risk stratification and identify treatment targets that can guide 
treatment initiation and escalation in ES patients.
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